1 / 40

THE BALANCE OF BENEFITS & RISK OF ORAL CONTRACEPTIVES-USE

THE BALANCE OF BENEFITS & RISK OF ORAL CONTRACEPTIVES-USE. Prof.Dr. Merih BAYRAM Gazi Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı. Types of Hormonal Contraceptives. Combination Oral Contraceptives. Progestin-only Contraceptives.

zocha
Download Presentation

THE BALANCE OF BENEFITS & RISK OF ORAL CONTRACEPTIVES-USE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE BALANCE OF BENEFITS & RISK OF ORAL CONTRACEPTIVES-USE Prof.Dr. Merih BAYRAM Gazi Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı

  2. Types of Hormonal Contraceptives Combination Oral Contraceptives Progestin-only Contraceptives Thickening of cervical mucus, decrease sperm penetration Endometrial alterations to impair implantation Decreasing the frequency of GnRH pulses Inhibit ovulation by suppressing HPO function Modify mid-cycle surges of LH/FSH Diminish ovarian hormone production • LH and FSH levels are suppressed • Mid-cycle surge of LH is absent • Endogenous steroid levels are diminished • Inhibit ovulation • Progesterone diminishes the frequency of GnRH pulses • Thicken cervical mucus to impede sperm transit • Produce unfavorable endometrial changes for ovum implantation

  3. Types of Hormonal Contraceptives Combination Oral Contraceptives Progestin-only Contraceptives Theoretical Efficacy is 99 % Norethindrone Norgestrel MPA Theoretical Efficacy is 99.9 % Estrogens: Ethinyl estradiol Mestranol Progestins: 19-nor compounds Estranes: Norethindrone Lynestrenol Gonanes: Levonorgestrel Desogestrel Gestodene Norgestimate Spironolactone derivate:Drospirenone

  4. Combination Oral Contraceptives Cardiovascular effects • Any increased risk of MI in past users • Higher risk of MI in current users • The more increased risk of MI in COC-users than non-users OR 2.48 (95% CI, 1.91-3.22) • Insignificant risk of MI in past users versus non-users OR 1.15 (95% CI, 0.98-1.35) • The OR with second-generation 2.5 (CI 1.5-4.1) was higher than third-generation with OR 1.3 (CI 0.7-2.5) • Hypertension, smoking and hyperchlosterolemia, the factors increasing the risk of MI Kiley J,Hammond C. Clin Obstet Gynecol,2007:50:868 Tanis BJ,et al. N Engl Med.2001;345:1787

  5. Combination Oral Contraceptives Cardiovascular effects • Hypertension in 4% to 5% of normotensive women with early high-dose COC • Increase of hypertension in 10% to 15% of preexisting hypertensive women with early high-dose COC • The much lower incidence with newer low-dose preparations • The increased serum HDL and LDL levels with estrogens and the opposite effect with progestins • No significant change in total serum cholesterol or lipoprotein profils, but slight increases in triglycerides with low-dose preparations Godmann-Gilmann’s, The Pharmacologyical Basis of Therapeutics 2006

  6. Cardiovascular Mortality Risk with Smoking and COC-use Oral contraceptive nonuser Oral contraceptive user Cases per 100,000 Woman-Years Nonsmoker Nonsmoker Smoker Smoker Attributable Risk/100,000 User-Years 3.03 19.4 0.06 1.73 ≥ 35 years of age < 35 years of age Sherif K. Am J Obstet Gynecol. 1999;180(Pt 2):S343-S348.

  7. Progestin-Only ContraceptivesCardiovascular effects • No effect on blood pressure • Decreased HDL levels and increased LDL levels Godmann-Gilmann’s, The Pharmacologyical Basis of Therapeutics 2006

  8. Combination Oral ContraceptivesCancers • The incidence of cancer of endometrial, cervical, ovarian, breast and liver may increase because of growth-promoting effects of estrogens • About twofold risk of cervical cancer in long-term users (>5 years) • About twofold risk of liver cancer after 4 to 8 years of use Moodley J,2004, Godmann-Gilmann’s, The Pharmacologyical Basis of Therapeutics 2006

  9. Oral Contraceptive Use and Gynecological Carcinomas *Comparison for >97 monthsof users with nonusers. †Age-adjusted comparison of women ever using an oral contraceptive with women who never used one. Vessey M, Painter R. Br J Cancer. 2006;95:385-389.

  10. Combination Oral ContraceptivesCancers • The low risk of breast cancer in women of childbearing age , RR: 1.1 to 1.2 • No affect on the incidence of breast cancer with duration of use, type of component, age at first use, parity • No difference in breast cancer incidence between past users and never users at 10 years after discontinuation • The similar incidence of the phenotype of breast cancer (lobular and ductal ) Newcomer LM,et al. Cancer Causes Control.2003;14:225 Nyante SJ,et al.Int J Cancer.2008;122:936

  11. Combination Oral ContraceptivesCancers • The Oxford Family Planning Study, a large cohort study of 17.032 women followed for up to 16 years, Breast cancer RR 1.0 (95% CI 0.8-1.1) • The meta-analyses of 54 worldwide studies, the Collaborative Group on Hormonal Factors in Breast Cancer; • a modest risk of increase during COC-use RR=1.24 (95% CI1.15-1.33) • 1 to 4 years after cessation of use RR=1.16 (95% CI 1.08-1.23) • 5 to 9 years after cessation of use RR=1.07 (95% CI 1.02-1.13) • No increased risk after cessation of 10 or more years of use Vessey M,Painter R. Br J Cancer,2006 ;95:385 Collaborative Group on Hormonal Factors in Breast Cancer.Lancet.1996;347:1713

  12. A Case-Control Study Shows No Increased Risk for Breast Cancer With Oral Contraceptive Use • NICHD Women’s CARE Study • Subjects: >9200 women from 35 to 64 years of age • Case-control study design: half of the subjects had a diagnosis of breast cancer • Study setting: metropolitan areas of Atlanta, Detroit, Los Angeles, Philadelphia, and Seattle • Study method: interview about oral contraceptive and hormone use • Neither current users (relative risk [RR] 1.0, confidence interval [CI] 0.8–1.3) nor previous users (RR 0.9, CI 0.8–1.0) had no increased incidence of breast cancer diagnosis • No difference was found between the high-dose (>50 µg) and the low-dose (<50 µg) estrogen formulations *National Institute of Child Health and Human Development Women’s Contraceptive and Reproductive Experiences Study Marchbanks PA, et al. NEJM.2002;346:2025-2032.

  13. Combination Oral ContraceptivesCancers • 40% less likely of ovarian cancer in users • 80% less likely of ovarian cancer in users of 10 years or more • It is unclear whether COC-user confers similar benefit in patients with the BRCA1 or BRCA2 mutations • 45% increased risk in carriers of BRCA1 • 25% increased risk in carriers of BRCA2 • COC reduce ovarian cancer risk in carriers of BRCA1 and BRCA2 mutations • 15% reduction with short-term oral contraceptive use (≥1 year) • 60% reduction with long-term oral contraceptive use (≥6 years) Vessey MP,Painter R.Br J Cancer.1995;71:1340 Whittemore AS, et al. Br J Cancer. 2004;91:1911-1915;Narod SA, et al. N Engl J Med. 1998;339:424-428

  14. Combination Oral ContraceptivesCancers • The mechanism of lowering the risk of ovarian cancer ; • Decrease of recurrent ovarian injury with suppression of ovulation • Chronic suppression of gonadotropin secretion • Greater protection with progestins Schildkraut JM, et al.J Natnl Cancer Inst.2002;94:32

  15. Collaborative Group an Epidemiological Studies of Ovarian Cancer.Lancet.2008;371:303

  16. Combination Oral ContraceptivesCancers The decrease of 50% incidence of endometrial cancer • 20% and 80% reduction after 1 year and 10 years use respectively • Adenocarcinoma and adenosquamous carcinoma, the most common endometrial carcinomas of reduced incidence with COC-use Kiley J,Hammond C.Clin Obstet Gynecol.2007;50:868

  17. Progestin-Only ContraceptivesCancers • Numerous human studies showing no any increases in breast, endometrial, cervical or ovarian cancer Westhoff C. Contraception. 2003;68:75

  18. Combination Oral ContraceptivesVenous Thromboembolism • The fourfold risk versus no use • OR : 3.2 (CI 2.3-4.3) with second-generation • OR : 4.8 (3.4-6.7) with third-generation • OR1.5 (CI 1.1-2.1) with third-generation products versus second-generation products • The risk of VTE is dose-dependent 50 mcg or more of EE Blickstein D,et al.Curr Opin Obstet Gynecol.2007;19:370

  19. Risks of Oral Contraceptives:Nonfatal Venous Thromboembolism Estimated Average Risk/ 100,000 Women/Year Non-Oral Contraceptive Users Pregnant Women Oral Contraceptive Users Food and Drug Administration. FDA Talk Paper. Nov. 24, 1995.

  20. Combination Oral ContraceptivesVenous Thromboembolism Additive factors of VTE together with COC • Hereditary thrombophilias • Factor V Leiden mutation OR: 6.4 to 99 • Smoking • Age Probably mechanisms: • Increase levels of D-dimers • Increase thrombin-activatable fibrinolysis inhibitor • Induce a prolongation of the clot lysis time • a blocking anti-factor XI antibody Mohllajee AP,et al.Contraception.2006;73:166

  21. Progestin-Only ContraceptivesVenous Thromboembolism • There is no evidence that the progestin-only preparations increase thromboembolic events • Progestin-only pill don’t change the fibrinolytic parameters Godmann-Gilmann’s, The Pharmacologyical Basis of Therapeutics 2006 Kemmeren JM, et al. Blood. 2004;103:927

  22. Combination Oral ContraceptivesStroke • Stroke is a rare event among COC-users ≥50 mcg EE RR=3.95 (95% CI,2.4-6.5) <50 mcg EE RR=2.19 (95% CI,1.1-4.2) • The risk of stroke twofolds among current COC-users, but do not correlate with increasing dose of estrogen or type of progestin • The relative risk of stroke in users of any type versus non-users 2.3 (CI 1.6-3.3) • First-generation OCs OR 1.7 (CI 0.7-4.4) • Second-generation OCs OR 2.4 (CI 1.6-3.7) • Third-generation OCs OR 2.0 (CI1.2-3.5) Kemmeren JM,et al.Stroke.2002;33:1202Kiley J,Hammond C.Clin Obstet Gynecol.2007;50:868

  23. Combination Oral ContraceptivesMetabolic Effects The effects of sex streoids on glucose metabolism and insulin sensitivity are complex: • High dose OC impaires glucose tolerance (increase in fasting glucose and insulin levels) and responses to glucose challenge • Low-dose COC may improve insulin sensitivity • High dose progestins raise LDL and reduce HDL levels • 100 mg of levonorgestrel exert undesirable effects on blood lipids • Desogestrel, norgestimate and gestodene improve HDL/LDL ratios Hatcher RA,et al.Contraseptive Tecnology. 18th ed.2004 Bushnell CD.Lancet Neurol.2005;4:743

  24. No statistical difference in weight gain (0.5 kg) between users of oral contraceptives (30 g EE) and nonusers Weight Gain and Oral Contraceptives: Controlled Studies Do Not Show Link Placebo-controlled double-blind crossover (N=380) ouble-blind crossover (N=380) Weight gain (5 lb) in ~ 25% of women; no significant difference between the placebo group and the users of oral contraceptive ( 50 g ethinylestradiol [EE]) Goldzieher et al., 1971 Reubinoff et al., Prospective, randomized (N=49) 1995 Gallo et al., No association between combination oral contraceptives and weight gain Systematic review of randomized controlled trials 2006 Huber LRB,et al., 2007 Goldzieher JW, et al. FertilSteril. 1971;22:609-623; Reubinoff BE, et al. FertilSteril. 1995;63:516-521;Gallo MF, et al. Cochrane Database Syst Rev. 2006;(1):CD003987. Brunner LRB and Toth J.Am J Epidemiology.2007;166:1307

  25. Progestin-Only ContraceptivesMetabolic Effects • Mood changes and weight gain have been reported Westhoff C. Contraception.2003;68:75

  26. Combination Oral ContraceptivesNoncontraceptive Benefits • Decrease of quantity of menstruel flow, severity of dysmenorrhea, acne, benign breast disease incidence and several other physical parameters Kiley J,Hammond C.Clin Obstet Gynecol.2007;4:868

  27. Combination Oral ContraceptivesMenstrual Benefits • Decrease menstrual and periovulatory pain by decreasing prostaglandin release • Control menorrhagia • 43% reduction in menstrual flow with 30 mcg EE/150 mcg levonorgestrel • Reduce the risk of iron deficiency anemia • Reduce the frequency and severity of menstrual associated mastalgia, mood dysphoria and fluid retention with drospirenone-containing formulations Larsson G,et al.Contraception.2002;46:327

  28. Combination Oral ContraceptivesBenign Breast Disease (BBD) • Benefits depend on the estrogen dose, progestin type and underlying breast pathology • The decrease risk for nonproliferative BBD with long-term-use • The decrease risk for proliferative BBD without atypia • Not seem to reduce risk of breast cancer between BBD and breast carcinoma, but may augment the risk • The degree of risk reduction is positively correlated with duration of use, >7 years-use reduce their risk by as much as 40% (RR 0.64, CI 0.47-0.87) Charreau I,et al.Eur J Cancer Prev.1993;2:147 Rohan TE,et al.Int J Cancer.1992;82:191 Collaborative Group on Hormonal Factors in Breast Cancer.Lancet.1996;347:1713

  29. Combination Oral ContraceptivesBone Mineral Density • Prevents osteoporosis with many mechanisms • Increase cortical and trabecular bone mass Kuohung W,et al.Contraception.2000;61:77 Vessey M,et al.Contraception.1998;57:231

  30. Progestin-Only Contraceptives Bone Mineral Density • There have been several reports of decreased bone density • BMD and BMC in oligomenorrheic or eumenorrheic female runners are yielded 43% reduction • The rate of stress fracture is 38% Cobb KLL,et al.Medicine & Science in Sports & Exercise.2007 ;39:1464

  31. Combination Oral ContraceptivesPelvic Inflammatory Disease Reduce the risk of acute pelvic inflammatory disease • 50% to 80% reduction in the risk of acute salpingitis among pill users • Proposed mechanisms: • tickening of cervical mucus • altered tubal motility • impeding ascent of pathogens • decreased menstruum to serve nidus for infection Rubin GL,et al.Am J Obstet Gynecol.1982;144:630 Wolner-Hassen P,et al.Obstet Gynecol.1985;66:233 Ness RB,et al.Am J Obstet Gynecol.1997;176:580

  32. Combination Oral ContraceptivesDermatologic Benefits •  Androgen secretion in the ovaries and adrenal glands through their estrogenic effects •  Production of testosterone •  Levels of free testosterone •  Production of dihydrotestosterone •  Sex hormone-binding globulin to bind androgens •  5-reductase activity • Reduce the incidence and severity of acne van derVange N, et al. Contraception.1990;41:345; Cassidenti DL, et al. Obstet Gynecol. 1991;78:103

  33. EE/LNG Oral Contraceptives Decrease Inflammatory Skin Lesions 0 Placebo EE/LNG *P<0.05 -5 Mean Change From Baseline in Inflammatory Lesion Counts * -10 * * -15 2 5 6 1 3 4 0 28-Day Cycle EE/LNG=20 µg ethinyl estradiol/100 µg levonorgestrel Adapted from Leyden J et al. J Am Acad Dermatol. 2002;47(3):399-409.

  34. Oral Contraceptives Containing 20-µg EthinylEstradiol Decrease the Total Number of Acne Lesions Baseline Cycle 3 Baseline Cycle 3 EE/NETA EE/LNG EE/LGN = 20 g ethinyl estradiol/100 g levonorgestrel; EE/NETA = 20 g ethinyl estradiol/1,000 g norethindrone acetate Thorneycroft IH, et al. Contraception. 1999;60:255-262. Thorneycroft IH, et al. Contraception. 1999;60:255-262.

  35. Oral Contraceptives Decrease Dysmenorrhea-Related Pain in Adolescents *P=0.004 vs. placebo * Mean (±SD) MMDQ Pain Score Baseline 3 Months MMDQ = Moos Menstrual Distress Questionnaire; Oral Contraceptive = 20 µg ethinyl estradiol/100 µg levonorgestrel. Davis AR, et al. Obstet Gynecol. 2005;106:97-104.

  36. Extended Use of the Contraceptive Ring: Premenstrual Symptom Improvement 28-day cycle 49-day cycle 91-day cycle 364-day cycle Study Exit Interviews (%) Menstrual Pain Less * Premenstrual Syndrome Less† Headache Less/Much Less† Overall Satisfaction *Compared with past contraceptive method use † Among those reporting a history of premenstrual syndrome Miller L, et al. Obstet Gynecol. 2005;106:473

  37. Adolescents’ Anticipated vs. Reported Side Effects: EE 20 µg/LNG 100 µg Formulation Anticipated at baseline Reported at 6 months Percent Breast Tenderness Weight Gain Spotting Nausea Mood Changes Headaches Symptom Rosenthal SL et al. 12th World Congress of Pediatric & Adolescent Gynecology. June 1998;Helsinki, Finland.

  38. Combination Oral ContraceptivesNoncontraceptive Benefits • COCs reduce the risk of ectopic pregnancy by inhibiting ovulation • Cycle-related: • Irregular cycles • Dysmenorrhea • Menorrhagia • Anemia • Functional ovarian cysts • Endometriosis, adenomyosis Adapted from Grimes DA et al, eds. Modern Contraception: Updatesfrom The Contraception Report. Emron;1997:1-100

  39. Conclusion Beneficial Effects with Combination Oral Contraceptives • Indisputably have beneficial effects on menorrhagia, dysmenorrhea, ovulatory pain, acne and hirsutism • Varying magnitude have preventive effects on salpingitis, endometriosis, adenomyosis and myomas • Lower the risk of endometrial, ovarian and possibly colon cancer • Increase bone mass • May reduce the risk of ovarian cysts, rheumatoid arthritis and benign breast disease • May have protective effect against atherosclerosis

  40. Conclusion Untoward Effects with Combination Oral Contraceptives • Cardiovascular effects hypertension myocardial infarction • Stroke ; ischemic or haemorrhagic • Venous trombosis and embolism, especially with third-generation • Cancers increase breast hepatocellular cervical • Endocrin and metabolic effect, impaires glucose tolerance and responses to glucose challenge • Special infections, HIV, HPV

More Related